Abstract:In AD, significant changes of hyperphosphorylated tau levels in CSF are found in AD patients. FDG-PET has the unique ability to estimate the local cerebral metabolic rate of glucose consumption, thus providing information on the distribution of neuronal death and synapse dysfunction in vivo. This is a double-blind, randomized, placebo-controlled study. 22 AD patients were randomly assigned to either the treatment or the placebo group. Plasma and cerebrospinal fluid (CSF) interleukin-10 (IL-10), amyloid ß-40 (Aß-40), total tau protein, measures of cognitive function tests such as the AD Assessment Scale-Cognitive Subscale (ADAS-cog), the Mini-Mental State Exam (MMSE) and the Severe Impairment Battery (SIB) as well as FDG-PET were acquired at the baseline and after the 24 week treatment period. The memantine dose was 20mg/day from initially 5mg/day in the treatment group. For the image analysis, the follow-up PET was realigned to the baseline scan for each subject and both were normalized to the standard brain template using SPM8. The two groups did not differ in their age (placebo group 64.7 ± 11.5 vs treatment group 65.7 ± 12.5), gender (female/male 7/4 vs 7/4) and education (placebo group 7.2 ± 2.4 vs treatment group 6.9 ± 2.1). MMSE score (p = 0.02), ADAS-Cog (p = 0.03) and total SIB (p = 0.05) were statistically different between the two groups at week 24 though they were not at baseline (p = 0.08, 0.1 and 0.2 respectively). The change of SIB score was statistically different between the two groups (p = 0.037). The Plasma and CSF IL-10, Aß-40, total tau protein were not statistically different both at baseline and at week 24. The placebo group had significant FDG uptake decline in precuneus, posterior cingulate, temporal and occipital regions (p = 0.005 uncorrected). In comparison to the placebo group, the memantine treatment group either had a reduced decline in posterior cingulate and temporal or showed increase in FDG uptake at week 24 in precuneus and temporal (p = 0.005 uncorrected). Findings from this RCT support the possibility that memantine treatment in moderately to severely affected AD patients is associated with both clinical improvement and smaller CMRgl decline in AD-affected brain regions. Additional studies with larger samples and more frequent measurements are needed to confirm these findings.

Increases in CBF by Donepezil treatment Enhance Cingulate Functional Network activity in Mild Alzheimerâ€ TM s Disease

Regulating Effect of CBF on Memory in Cognitively Normal Older Adults with Different ApoE Genotype: the Alzheimer’s Disease Neuroimaging Initiative (ADNI)

Temporal Dynamic Changes of Intrinsic Brain Activity Associated with Cognitive Reserve in Prodromal Alzheimer's Disease.

Increased Apparent Blood Flow and Volume of the Choroid Plexus in the Alzheimer’s Disease Patients

Changes in Regional Cerebral Blood Flow and Functional Connectivity in the Cholinergic Pathway Associated with Cognitive Performance in Subjects with Mild Alzheimer's Disease after 12-Week Donepezil Treatment

Effects of Cerebral Blood Flow and White Matter Integrity on Cognition in CADASIL Patients

The increased effective connectivity from left middle occipital gyrus to right medial septum/diagonal bands in AD patients after donepezil intervention

Enhanced Regional CBF in Patients with Mild Alzheimer ’ s Disease after Three Months of Aricept ® Treatment

Cholinergic Enhancement of Brain Activation in Mild Cognitive Impairment during Episodic Memory Encoding

Increased Functional Connectivity Between Nucleus Basalis of Meynert and Amygdala in Cognitively Intact Elderly along the Alzheimer’s Continuum

IC-P3-233: the Effects of Donepezil on Alzheimer's Disease: A Diffusion Tensor Imaging Study at 3T

P2-105: the Effects of Donepezil on Alzheimer's Disease: A Diffusion Tensor Imaging Study at 3T

Recovery of hippocampal network connectivity correlates with cognitive improvement in mild Alzheimer's disease patients treated with donepezil assessed by resting-state fMRI

Effects of APOE epsilon 2 allele on basal forebrain functional connectivity in mild cognitive impairment

Brain mapping activity and mental performance after chronic treatment with CDP-choline in Alzheimer's disease

IC-P-060: Decreased Intrinsic Functional Network in Cognitively Intact Elderly APOE-E4 Carriers Measured by Eigenvector Centrality Mapping

Association between long-term donepezil treatment and brain regional amyloid and tau burden among individuals with mild cognitive impairment assessed using <SUP>18</SUP>F-AV-45 and <SUP>18</SUP>F-AV-1451 PET

Disrupted Regional Cerebral Blood Flow, Functional Activity and Connectivity in Alzheimer's Disease: A Combined ASL Perfusion and Resting State Fmri Study.

Disrupted Regional Cerebral Blood Flow, Functional Activity and Connectivity in Alzheimer’s Disease: A Combined ASL Perfusion and Resting State fMRI Study

Long-Term Effect of Acetylcholinesterase Inhibitors on the Dorsal Attention Network of Alzheimer's Disease Patients: A Pilot Study Using Resting-State Functional Magnetic Resonance Imaging

Changes of biological markers and brain PET imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: A 24-week double-blind, randomized, placebo-controlled study